Epidepride	Epidepride	NN	B-NP	O	
[	[	(	O	O	
(	(	(	O	O	
S	S	NN	B-NP	O	
)	)	)	O	O	
-	-	HYPH	O	O	
(	(	(	O	O	
-	-	SYM	O	O	
)	)	)	O	O	
-N-	-N-	NN	B-NP	O	
(	(	(	O	O	
[	[	(	O	O	
1-ethyl-2-pyrrolidinyl	1-ethyl-2-pyrrolidinyl	NN	B-NP	O	
]	]	)	I-NP	O	
methyl	methyl	NN	I-NP	O	
)	)	)	O	O	
-5-iodo-2	-5-iodo-2	CD	B-NP	O	
,	,	,	O	O	
3-dimethoxybenza	3-dimethoxybenza	NN	B-NP	O	
mide	mide	NN	I-NP	O	
]	]	)	O	O	
binds	bind	VBZ	B-VP	O	
with	with	IN	B-PP	O	
a	a	DT	B-NP	O	
picomolar	picomolar	JJ	I-NP	O	
affinity	affinity	NN	I-NP	O	
(	(	(	O	O	
Ki	Ki	NN	B-NP	O	
=	=	SYM	B-VP	O	
24	24	CD	B-NP	O	
pM	pM	NN	I-NP	O	
)	)	)	O	O	
to	to	TO	B-PP	O	
the	the	DT	B-NP	O	
dopamine	dopamine	NN	I-NP	B-protein	
D2	D2	NN	I-NP	I-protein	
receptor	receptor	NN	I-NP	I-protein	
.	.	.	O	O	
Iodine-123-labeled	Iodine-123-labeled	JJ	B-NP	O	
epidepride	epidepride	NN	I-NP	O	
has	have	VBZ	B-VP	O	
been	be	VBN	I-VP	O	
used	use	VBN	I-VP	O	
previously	previously	RB	B-ADVP	O	
to	to	TO	B-VP	O	
study	study	VB	I-VP	O	
striatal	striatal	JJ	B-NP	O	
and	and	CC	I-NP	O	
extrastriatal	extrastriatal	JJ	I-NP	B-protein	
dopamine	dopamine	NN	I-NP	I-protein	
D2	D2	NN	I-NP	I-protein	
receptors	receptor	NNS	I-NP	I-protein	
with	with	IN	B-PP	O	
single	single	JJ	B-NP	O	
photon	photon	NN	I-NP	O	
emission	emission	NN	I-NP	O	
computed	compute	VBN	B-VP	O	
tomography	tomography	NN	B-NP	O	
(	(	(	O	O	
SPECT	SPECT	NN	B-NP	O	
)	)	)	O	O	
.	.	.	O	O	
Our	Our	PRP$	B-NP	O	
aim	aim	NN	I-NP	O	
was	be	VBD	B-VP	O	
to	to	TO	B-VP	O	
label	label	VB	I-VP	O	
epidepride	epidepride	NN	B-NP	O	
with	with	IN	B-PP	O	
carbon-11	carbon-11	NN	B-NP	B-protein	
for	for	IN	B-PP	O	
comparative	comparative	JJ	B-NP	O	
quantitative	quantitative	JJ	I-NP	O	
studies	study	NNS	I-NP	O	
between	between	IN	B-PP	O	
positron	positron	NN	B-NP	O	
emission	emission	NN	I-NP	O	
tomography	tomography	NN	I-NP	O	
(	(	(	O	O	
PET	PET	NN	B-NP	B-protein	
)	)	)	O	O	
and	and	CC	O	O	
SPECT	SPECT	NN	B-NP	O	
.	.	.	O	O	
Epidepride	Epidepride	NN	B-NP	O	
was	be	VBD	B-VP	O	
synthesized	synthesize	VBN	I-VP	O	
from	from	IN	B-PP	O	
its	its	PRP$	B-NP	O	
bromo-analogue	bromo-analogue	JJ	I-NP	O	
FLB	FLB	NN	I-NP	O	
457	457	CD	I-NP	O	
via	via	IN	B-PP	O	
the	the	DT	B-NP	O	
corresponding	correspond	VBG	I-NP	O	
trimethyl-tin	trimethyl-tin	NN	I-NP	O	
derivative	derivative	NN	I-NP	O	
.	.	.	O	O	
In	In	IN	B-PP	O	
an	an	DT	B-NP	O	
alternative	alternative	JJ	I-NP	O	
synthetic	synthetic	JJ	I-NP	O	
pathway	pathway	NN	I-NP	O	
,	,	,	O	O	
the	the	DT	B-NP	O	
corresponding	correspond	VBG	I-NP	O	
substituted	substitute	VBN	B-VP	O	
benzoic	benzoic	JJ	B-NP	O	
acid	acid	NN	I-NP	O	
was	be	VBD	B-VP	O	
reacted	react	VBN	I-VP	O	
with	with	IN	B-PP	O	
the	the	DT	B-NP	O	
optically	optically	RB	I-NP	O	
pure	pure	JJ	I-NP	O	
aminomethylpyrrolidine-derivative	aminomethylpyrrolidine-derivative	NN	I-NP	O	
.	.	.	O	O	
Demethylation	Demethylation	NN	B-NP	O	
of	of	IN	B-PP	O	
epidepride	epidepride	NN	B-NP	O	
gave	give	VBD	B-VP	O	
the	the	DT	B-NP	O	
desmethyl-derivative	desmethyl-derivative	NN	I-NP	O	
,	,	,	O	O	
which	which	WDT	B-NP	O	
was	be	VBD	B-VP	O	
reacted	react	VBN	I-VP	O	
with	with	IN	B-PP	O	
[	[	(	B-NP	O	
11C	11C	NN	I-NP	O	
]	]	)	I-NP	O	
methyl	methyl	NN	I-NP	O	
triflate	triflate	NN	I-NP	O	
.	.	.	O	O	
Total	Total	JJ	B-NP	O	
radiochemical	radiochemical	JJ	I-NP	O	
yield	yield	NN	I-NP	O	
was	be	VBD	B-VP	O	
40-50	40-50	CD	B-NP	O	
%	%	NN	I-NP	O	
within	within	IN	B-PP	O	
a	a	DT	B-NP	O	
total	total	JJ	I-NP	O	
synthesis	synthesis	NN	I-NP	O	
time	time	NN	I-NP	O	
of	of	IN	B-PP	O	
30	30	CD	B-NP	O	
min	min	NN	I-NP	O	
.	.	.	O	O	
The	The	DT	B-NP	O	
specific	specific	JJ	I-NP	O	
radioactivity	radioactivity	NN	I-NP	O	
at	at	IN	B-PP	O	
the	the	DT	B-NP	O	
end	end	NN	I-NP	O	
of	of	IN	B-PP	O	
synthesis	synthesis	NN	B-NP	O	
was	be	VBD	B-VP	O	
37-111	37-111	CD	B-NP	O	
GBq/micromol	GBq/micromol	NN	I-NP	O	
(	(	(	O	O	
1	1	CD	B-NP	O	
,	,	,	I-NP	O	
000-3	000-3	CD	I-NP	O	
,	,	,	I-NP	O	
000	000	CD	I-NP	O	
Ci/mmol	Ci/mmol	NN	I-NP	O	
)	)	)	O	O	
.	.	.	O	O	
Human	Human	JJ	B-NP	O	
postmortem	postmortem	JJ	I-NP	O	
whole-hemisphere	whole-hemisphere	JJ	I-NP	O	
autoradiography	autoradiography	NN	I-NP	O	
demonstrated	demonstrate	VBD	B-VP	O	
dense	dense	JJ	B-NP	O	
binding	binding	NN	I-NP	O	Mention 104	
in	in	IN	B-PP	O	
the	the	DT	B-NP	O	
caudate	caudate	JJ	I-NP	O	
putamen	putaman	NNS	I-NP	O	
,	,	,	O	O	
and	and	CC	O	O	
also	also	RB	B-ADVP	O	
in	in	IN	B-PP	O	
extrastriatal	extrastriatal	JJ	B-NP	O	
areas	area	NNS	I-NP	O	
such	such	JJ	B-PP	O	
as	as	IN	I-PP	O	
the	the	DT	B-NP	O	
thalamus	thalamus	NN	I-NP	O	
and	and	CC	O	O	
the	the	DT	B-NP	O	
neocortex	neocortex	NN	I-NP	O	
.	.	.	O	O	
The	The	DT	B-NP	O	Mention 105	
binding	binding	NN	I-NP	O	
was	be	VBD	B-VP	O	
inhibited	inhibit	VBN	I-VP	O	
by	by	IN	B-PP	O	
unlabeled	unlabeled	JJ	B-NP	O	
raclopride	raclopride	NN	I-NP	O	Mention 106	
.	.	.	O	O	
PET	PET	NN	B-NP	O	
studies	study	NNS	I-NP	O	
in	in	IN	B-PP	O	
a	a	DT	B-NP	O	
cynomolgus	cynomolgus	NN	I-NP	O	
monkey	monkey	NN	I-NP	O	
demonstrated	demonstrate	VBD	B-VP	O	
high	high	JJ	B-NP	O	
uptake	uptake	NN	I-NP	O	
in	in	IN	B-PP	O	
the	the	DT	B-NP	O	
striatum	striatum	NN	I-NP	O	
and	and	CC	B-PP	O	
in	in	IN	B-PP	O	
several	several	JJ	B-NP	O	
extrastriatal	extrastriatal	JJ	I-NP	O	
regions	region	NNS	I-NP	O	
.	.	.	O	O	
At	At	IN	B-PP	O	
90	90	CD	B-NP	O	
min	min	NN	I-NP	O	
after	after	IN	B-PP	O	
injection	injection	NN	B-NP	O	
,	,	,	O	O	
uptake	uptake	NN	B-NP	O	
in	in	IN	B-PP	O	
the	the	DT	B-NP	O	
striatum	striatum	NN	I-NP	O	
,	,	,	I-NP	O	
thalamus	thalamus	NN	I-NP	O	
and	and	CC	I-NP	O	
neocortex	neocortex	NN	I-NP	O	
was	be	VBD	B-VP	O	
about	about	RB	B-NP	O	
11	11	CD	I-NP	O	
,	,	,	I-NP	O	
4	4	CD	I-NP	O	
,	,	,	O	O	
and	and	CC	O	O	
2	2	CD	B-NP	O	
times	time	NNS	I-NP	O	
higher	high	JJR	I-ADJP	O	
than	than	IN	B-PP	O	
in	in	IN	B-PP	O	
the	the	DT	B-NP	O	
cerebellum	cerebellum	NN	I-NP	O	
,	,	,	O	O	
respectively	respectively	RB	B-ADVP	O	
.	.	.	O	O	
Pretreatment	Pretreatment	NN	B-NP	O	
experiment	experiment	NN	I-NP	O	
with	with	IN	B-PP	O	
unlabeled	unlabeled	JJ	B-NP	O	
raclopride	raclopride	NN	I-NP	O	Mention 107	
(	(	(	O	O	
1	1	CD	B-NP	O	
mg/kg	mg/kg	NN	I-NP	O	
)	)	)	O	O	
inhibited	inhibit	VBD	B-VP	O	
50-70	50-70	CD	B-NP	O	
%	%	NN	I-NP	O	
of	of	IN	B-PP	O	
[	[	(	B-NP	O	Mention 108	
11C	11C	NN	I-NP	O	
]	]	)	I-NP	O	
epidepride	epidepride	NN	I-NP	O	
binding	binding	NN	I-NP	O	
.	.	.	O	O	
The	The	DT	B-NP	O	
fraction	fraction	NN	I-NP	O	
of	of	IN	B-PP	O	
unchanged	unchanged	JJ	B-NP	O	
[	[	(	I-NP	O	
11C	11C	NN	I-NP	O	
]	]	)	I-NP	O	
epidepride	epidepride	NN	I-NP	O	
in	in	IN	B-PP	O	
monkey	monkey	NN	B-NP	O	
plasma	plasma	NN	I-NP	O	
determined	determine	VBN	B-VP	O	
by	by	IN	B-PP	O	
a	a	DT	B-NP	O	
gradient	gradient	NN	I-NP	O	
high	high	JJ	I-NP	O	
performance	performance	NN	I-NP	O	
liquid	liquid	NN	I-NP	O	
chromatography	chromatography	NN	I-NP	O	
(	(	(	O	O	
HPLC	HPLC	NN	B-NP	O	
)	)	)	O	O	
method	method	NN	B-NP	O	
was	be	VBD	B-VP	O	
about	about	RB	B-NP	O	
30	30	CD	I-NP	O	
%	%	NN	I-NP	O	
of	of	IN	B-PP	O	
the	the	DT	B-NP	O	
total	total	JJ	I-NP	O	
radioactivity	radioactivity	NN	I-NP	O	
at	at	IN	B-PP	O	
30	30	CD	B-NP	O	
min	min	NN	I-NP	O	
after	after	IN	B-PP	O	
injection	injection	NN	B-NP	O	
of	of	IN	B-PP	O	
[	[	(	B-NP	O	
11C	11C	NN	I-NP	O	
]	]	)	I-NP	O	
epidepride	epidepride	NN	I-NP	O	
.	.	.	O	O	
The	The	DT	B-NP	O	
availability	availability	NN	I-NP	O	
of	of	IN	B-PP	O	
[	[	(	O	O	
11C	11C	NN	B-NP	O	
]	]	)	O	O	
epidepride	epidepride	NN	B-NP	O	
allows	allow	VBZ	B-VP	O	
the	the	DT	B-NP	O	
PET-verification	PET-verification	NN	I-NP	O	
of	of	IN	B-PP	O	
the	the	DT	B-NP	O	
data	datum	NNS	I-NP	O	
obtained	obtain	VBN	B-VP	O	
from	from	IN	B-PP	O	
quantitation	quantitation	NN	B-NP	O	
studies	study	NNS	I-NP	O	
with	with	IN	B-PP	O	
SPECT	SPECT	NN	B-NP	B-protein	
.	.	.	O	O	
